论文部分内容阅读
目的 观察脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效、安全性。方法 随机单盲对照观察脱氢表雄酮硫酸酯 (DHEAS)服用六个月前后骨密度 (BMD)、血生化指标、骨吸收指标和骨形成指标 ,副作用等方面的变化。结果 治疗后治疗组脱氢表雄酮硫酸酯 (DHEAS)、类胰岛素生长因子 Ⅰ (IGF Ⅰ )较治疗前分别提高 (93 75±16 1) %、(17 71± 4 2 ) % ,较对照组明显提高 (P <0 0 1)。腰 2、腰 3、腰 4的骨密度 (BMD)较治疗前分别提高(2 6 5± 0 6 2 ) %、(2 70± 0 4 8) %、(3 10± 0 4 1) % ,腰 2 - 4较治疗前提高 (2 82± 0 37) % ,股骨颈的BND较治疗前提高 (2 32± 0 32 ) %。腰 2、腰 3、腰 4、腰 2 4、股骨颈的BMD上升幅度较大与对照组差别有显著性 (P <0 0 5 ,0 0 1)。游离睾丸酮 (FT)、雌二醇 (E2 )、前列特异抗原 (PSA)则无明显影响。结论 脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效安全可靠 ,无不良反应。
Objective To observe the efficacy and safety of dehydroepiandrosterone sulfate in the treatment of male osteoporosis. Methods The changes of bone mineral density (BMD), blood biochemical indexes, bone resorption index, bone formation index and side effects of DHEAS were observed by random single-blind control. Results After treatment, the levels of DHEAS and IGF Ⅰ increased by (93 75 ± 16 1)% and (17 71 ± 42 2%), respectively, Group was significantly higher (P <0.01). The BMD of lumbar 2, lumbar 3 and lumbar 4 increased by (2650 ± 262)%, (3270 ± 048)%, (3110 ± 041)%, The waist 2 - 4 was increased by (2 82 ± 0 37)% compared with that before treatment, and the BND of femoral neck was (2 32 ± 0 32)% higher than that before treatment. Lumbar 2, lumbar 3, lumbar 4, lumbar 2 4, femoral neck BMD increased significantly larger and the difference between the control group was significant (P <0 0 5, 0 0 1). Free testosterone (FT), estradiol (E2), prostatic specific antigen (PSA) had no significant effect. Conclusion Dehydroepiandrosterone sulfate treatment of male osteoporosis efficacy is safe and reliable, no adverse reactions.